RxDoctor Payments Data

Broc White, MD

Family Medicine · Lander, WYNPI 1073856225

Payments from drug & device makers

$380in general payments, 2019–2025

Across 23 payments — averaging $16.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$138
  • AbbVie$106
  • AstraZeneca$49
  • Novo Nordisk$28
  • Sunovion Pharmaceuticals Inc.$22
  • Pfizer$21
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$36496%
  • Education$164%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK8$138
AbbVie(2 entities)5$106
AstraZeneca3$49
Novo Nordisk2$28
Sunovion Pharmaceuticals Inc.2$22
Pfizer1$21
Organon2$15

How this compares

$380 in reported general payments places this provider in the 65th percentile of 237 family medicine providers in Wyoming.

See all family medicine providers in Wyoming

Medicare billing

Part B allowed, 2024
$255,973
Medicare patients
485
Services billed
10,727

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban175$147,326
OzempicSemaglutide64$83,696
MounjaroTirzepatide36$41,963
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$37,273
TrulicityDulaglutide32$33,446
JardianceEmpagliflozin45$30,063
XareltoRivaroxaban24$21,358
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$19,168
FarxigaDapagliflozin Propanediol12$11,386
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog29$10,968
Bydureon BciseExenatide Microspheres12$9,767
JanuviaSitagliptin Phosphate23$8,701
Tresiba Flextouch U-100Insulin Degludec18$6,921
Ventolin HfaAlbuterol Sulfate61$4,117
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$2,961

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$147,326175 claims
Novo NordiskOzempic$28$83,69664 claims
GSKTrelegy Ellipta$138$37,27333 claims
AstraZenecaBreztri Aerosphere, Farxiga$49$30,55530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 237 family medicine providers in Wyoming.

Other family medicine in Lander

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →